S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
OncLive® On Air
00:00
Sacituzumab deruxtecan (SAR‑TMT) early and OPTITRope
Heather McArthur reviews SAC‑TMT promising PFS and OS in heavily pretreated TNBC from OPTITrope‑REST01.
Play episode from 19:27
Transcript
